|
AVLN Avalyn Pharma Inc 1540171 |
| Income Statement |
|
Net Income
|
2026-06-30
|
$-28,935,000.00 |
| Balance Sheet |
|
Current Assets
|
$357,988,000.00 |
|
Assets
|
$425,448,000.00 |
|
Current Liabilities
|
$10,809,000.00 |
|
Liabilities
|
$27,102,000.00 |
|
Equity
|
$398,346,000.00 |
|
Shares Out
|
44333094.00 |
| Cash Flow Statement |
|
Operating Cash Flow
|
$-55,967,000.00 |
|
Investing Cash Flow
|
$-63,686,000.00 |
| Market Analysis |
Market Cap
|
$1,646,087,780.22 |
|
Price
|
$37.13 |
|
BVPS
|
8.99 |
|
PB
|
4.13 |
|
EPS
|
-0.98 |
|
FCF
|
$-56,554,000.00 |
|
| Dividends |
|
Dividend Data Last Updated
|
2026-09-01 09:32:33 |
|
|
| Earnings |
|
Earnings Last Updated
|
2026-09-14 10:01:23 |
|
|
|
Find a discrepancy? The most accurate way to find company fundamental data is to view AVLN documents filed with the SEC.
AVLN Filings
Clear
